Coding and Non-Coding Transcriptomic Landscape of Aortic Complications in Marfan Syndrome.
Marfan syndrome
biomarker
chromatin changes
clinical guideline
epigenome
heritable aortic aneurysms and dissection
protein-coding and non-coding RNAs
single-cell RNA-seq
thoracic aortic aneurysm
transcriptome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
received:
20
05
2024
revised:
21
06
2024
accepted:
27
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
Marfan syndrome (MFS) is a rare congenital disorder of the connective tissue, leading to thoracic aortic aneurysms (TAA) and dissection, among other complications. Currently, the most efficient strategy to prevent life-threatening dissection is preventive surgery. Periodic imaging applying complex techniques is required to monitor TAA progression and to guide the timing of surgical intervention. Thus, there is an acute demand for non-invasive biomarkers for diagnosis and prognosis, as well as for innovative therapeutic targets of MFS. Unraveling the intricate pathomolecular mechanisms underlying the syndrome is vital to address these needs. High-throughput platforms are particularly well-suited for this purpose, as they enable the integration of different datasets, such as transcriptomic and epigenetic profiles. In this narrative review, we summarize relevant studies investigating changes in both the coding and non-coding transcriptome and epigenome in MFS-induced TAA. The collective findings highlight the implicated pathways, such as TGF-β signaling, extracellular matrix structure, inflammation, and mitochondrial dysfunction. Potential candidates as biomarkers, such as miR-200c, as well as therapeutic targets emerged, like Tfam, associated with mitochondrial respiration, or miR-632, stimulating endothelial-to-mesenchymal transition. While these discoveries are promising, rigorous and extensive validation in large patient cohorts is indispensable to confirm their clinical relevance and therapeutic potential.
Identifiants
pubmed: 39000474
pii: ijms25137367
doi: 10.3390/ijms25137367
pii:
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health projects Ricerca Corrente
ID : 2024 1.07.128
Organisme : Italian Ministry of Health projects Ricerca Finalizzata
ID : RF-2019-12368521
Organisme : POS T4 CAL.HUB.RIA
ID : cod. T4-AN-09
Organisme : Next Generation EU-NRRP M6C2 Inv. 2.1
ID : PNRR-MAD-2022-12375790
Organisme : Next Generation EU PNRR
ID : PNRR/2022/C9/MCID/I8 FibroThera
Organisme : Telethon Foundation
ID : # GGP19035A
Organisme : AFM-Telethon grant
ID : # 23054